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Abstract
Several reports point to the beneficial effects of repetitive transcranial magnetic stimulation (rTMS) in the treatment of 
resistant obsessive–compulsive disorder (OCD). This study aimed to evaluate the safety and efficacy of rTMS targeting the 
dmPFC in the treatment of treatment-resistant OCD patients. Twelve patients received 20 sessions of low-frequency (LF) 
rTMS (1 Hz, 1200 pulses) in a twice daily protocol during 10 weekdays. Y-BOCS and IDS scores modestly but significantly 
decreased after treatment and at follow-up and HADS anxiety improved at follow-up. LF rTMS may improve OCD, anxiety, 
and depressive symptoms in treatment-resistant OCD and was a safe and well-tolerated treatment.
Keywords Obsessive–compulsive disorder · Repetitive transcranial magnetic stimulation · Safety · Efficacy
Introduction
With a lifetime prevalence of 1–3% obsessive–compulsive 
disorder (OCD) is a chronic and disabling psychiatric dis-
order, with considerable burden for the individual and soci-
ety [1]. Current treatment strategies include high doses of 
serotonin reuptake inhibitors (SRIs) including clomipramine 
and/or cognitive–behavioral therapy [2], often augmented 
with antipsychotics [3]. Despite various treatment strate-
gies, treatment resistance occurs in 30%–40% [4]. Recently, 
several reports point to repetitive transcranial magnetic 
stimulation (rTMS) as a potential noninvasive alternative 
for treatment-resistant OCD, targeting the dorsomedial pre-
frontal cortex (dmPFC) [5], the mPFC [6], the orbitofrontal 
cortex, or the supplementary motor area [7]. Moreover, FDA 
approved deep TMS with H7 coil as an adjunctive treatment 
of OCD in 2018, although NICE guidelines still do not advo-
cate the use of rTMS within a clinical context [8].
Since accelerated rTMS (arTMS), where multiple rTMS 
sessions per day are administered, has showed rapid clinical 
improvements in depression [15, 16], we aimed to evaluate 
the safety and efficacy of twice daily LF rTMS targeting the 
dmPFC in treatment-resistant OCD patients. It has been sug-
gested that an inhibitory LF rTMS protocol [9] suppresses 
the overactive regions in the dmPFC [10–13] normalizing 
the pathologically overactive cortico-striato-thalamic-corti-
cal (CSTC) circuitry in OCD [14].
Methods
Five male and seven female patients (mean age = 36.1, 
sd = 10.58 years, range 19–53) with a mean symptom dura-
tion of 20.3 years (sd = 10.76 years, range 4–45) partici-
pated in the study after giving written informed consent. 
All patients were recruited at the psychiatric services of 
the Ghent University Hospital. They were diagnosed with 
OCD using the Mini International Neuropsychiatric Inter-
view (M.I.N.I.) [17] and were regarded as treatment resistant 
because of at least two previous failed antidepressant tri-
als (mean = 3.8, sd = 1.01 failed trials). Moreover, 11 of the 
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12 patients had been unsuccessfully treated with cognitive 
behavioral therapy. All patients were on psychotropic medi-
cation [SSRI’s (58.3%), venlafaxine (8.3%) or clomipramine 
(33.3%)], which were combined with antipsychotics in five 
patients. Psychopharmacological treatment was kept stable 
for at least 12 weeks [except for two patients (4 weeks) and 
one patient (8 weeks)] before and during the rTMS. Changes 
in medication during the rTMS were considered as dropout 
from the study. Twenty LF-rTMS sessions (two sessions per 
day (twice daily) during 10 weekdays) were applied to the 
dmPFC under neuroguidance (X0 Y + 60 Z + 60) using a 
double cone coil (Magstim Company Limited, Minneapolis, 
USA) with a stimulation intensity of 100% of the exten-
sor halluces longus muscle resting motor threshold. Resting 
motor threshold (rMT) from foot is preferred for dmPFC 
rTMS as the foot region of motor cortex lies at similar depth 
from scalp as dmPFC. In each session, patients received a 
total number of 1200 pulses at a rate of 1 Hz with train 
duration of 150 s and intertrain interval of 120 s (in total: 
24.000 pulses). No patients dropped out of the treatment. 
The study was approved by the ethical committee of the 
Ghent University Hospital.
Patients were assessed before and after treatment (T0 
and T1 respectively) and 2  weeks after treatment (T2). 
Assessment included Y-BOCS [18], IDS-SR (Inventory of 
Depressive Symptomatology—self report) [19] and HADS 
(Hospital Anxiety and Depression Scale—self report) [20]. 
Response and partial response were defined as a decline 
of ≥ 35% and ≥ 25% on Y-BOCS, respectively, and remis-
sion as Y-BOCS score ≤ 12 [21]. Pre- and post-treatments 
scores were analyzed using the Wilcoxon rank-sum test for 
non-parametric testing. All data of 12 patients were included 
in the analysis except for the HADS data of one patient, 
which were missing. Adverse events as set forward by Rossi 
et al. [22] included transient irritability or euphoria, head-
ache, local pain, neck pain, toothache, tingling, changes in 
hearing, cognitive disturbances, local irritation and epileptic 
insults were rated on a scale from 0 (never) to 4 (almost 
continuously). Adverse events were assessed immediately 
after stimulation (T1) and at follow-up (T2).
Results
Y-BOCS and IDS scores significantly decreased 
after treatment (Z = − 3.061, p = 0.002, r = 0.63 and 
Z = − 2.018, p = 0.044, r = 0.41 respectively) and at fol-
low-up (Z = − 2.904, p = 0.004, r = 0.42 and Z = − 2.199, 
p = 0.028, r = 0.45 respectively). After treatment, 8% of the 
patients were in remission, whereas 33% and 50% of them 
showed response and partial treatment response, respec-
tively. At follow-up, the patients further improved with 
remission, response, and partial response rates of 17%, 42%, 
and 58%, respectively. Anxiety subscale of the HADS sig-
nificantly improved at follow-up (Z = − 2.099, p = 0.036). 
See also Table 1.
After treatment, several adverse effects of the rTMS were 
mentioned by ten patients: headache (eight patients), local 
pain (six patients), euphoria or irritability (five patients), 
toothache (four patients), tingling (four patients) and cog-
nitive disturbance (mainly excessive tiredness, which led 
sometimes to falling asleep during arTMS; four patients), 
local irritation (three patients), neck pain (two patients) 
and changes in hearing (one patient). Most of the adverse 
effects were reported as mild [“almost not” (score 1) to 
“sometimes” (score 2)] except for the headache and local 
pain, which was indicated by two patients to occur “often” 
(score 3) and by two patients “almost continuously” (score 
4), respectively. All these adverse effects were transient and 
none of them were reported at follow-up. No serious adverse 
events such as an epileptic insult occurred.
Discussion
This is the first rTMS protocol targeting twice daily the 
dmPFC in the treatment of treatment-resistant OCD. 
The results of our study are in line with the findings of 
Modirrousta et al. [6] and Dunlop et al. [5] indicating that 
dmPFC-rTMS may improve medication–refractory OCD 
symptoms. Moreover, OCD symptoms in our study already 
significantly decreased after 10 days instead of 4 weeks of 
treatment in both previously mentioned studies, despite 
using a lower stimulation intensity. The twice daily proto-
col may partly explain these results as similar effects have 
been reported in the treatment of depression [15, 16]. The 
role of the stimulation frequency remains unclear since both 
inhibitory as in our and Modirrousta study [6] and excita-
tory protocols as in the Dunlop study [5] may both lead to 
improvements in OCD symptoms [5]. A moderate to high 
effect size was found in our study, but a comparison with a 
Table 1  Obsessive–compulsive, anxiety and depressive symptoms 
before (T0) and immediately after arTMS (T1) and at follow-up after 
2 weeks (T2) in N = 12 patients (HADS: N = 11)
* p < .05 **p < .005
Baseline (T0) After treatment 
(T1)
At follow-up (T2)
Mean (SD) Mean (SD) Mean (SD)
Y-BOCS 30.6 (4.12) 22.0 (6.49) ** 21.1 (7.93) **
IDS-SR 33.6 (13.42) 28.3 (14.02) * 26.2 (13.93) *
HADS total 0.4 (5.78) 18.9 (5.49) 16.2 (6.51)
HADS anxiety 11.5 (3.59) 10.3 (3.46) 9.4 (4.18)*
HADS depres-
sion
8.8 (4.53) 8.6 (4.65) 6.8 (4.14)
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single daily rTMS protocol using the same parameters could 
not be made.
Furthermore, improvements of depressive and anxiety 
symptoms were observed, although they were inconsist-
ent across the different scales. IDS scores significantly 
decreased, but HADS-D (depression) did not. This may be 
caused by the psychometric differences between the scales. 
Five of the seven depression items of the HADS-D reflect 
several aspects of anhedonia [20]. The significant decrease 
of IDS and HADS-A (anxiety) may also be explained by 
the improvement of OCD symptomatology leading to less 
comorbid anxiety or depressive symptoms, or partly by treat-
ment placebo effects. Some authors have also pointed to a 
possible modulating effect on the hyperconnectivity between 
dmPFC and ventral striatum [5], leading to these benefits, 
although further investigation is warranted.
The twice daily rTMS (LF) protocol was well tolerated 
and only few typical adverse events—but no serious adverse 
events—were reported [22]. They included headache (67%) 
and local pain (50%) and were only mild and transient, not 
leading to any dropout of treatment. Some limitations war-
rant the generalizability of our results. They include the 
small sample size, the lack of long-term follow-up, and 
the combined pharmacological and rTMS treatment. Fur-
ther additional treatment effects of antidepressant change 
4 weeks before rTMS cannot be ruled out for two patients. 
Since no control condition was used, non-specific or placebo 
effects cannot be ruled out, although they tend to be lower 
(up to 20% of Y-BOCS scores).
To conclude, twice daily rTMS (LF) targeting dmPFC 
may rapidly improve OCD, anxiety and depressive symp-
toms in treatment-resistant OCD. It was further well toler-
ated by the patients. Future large placebo-controlled clinical 
trials contrasting single to double dose LF rTMS are needed 
to substantiate the assumption that twice daily results in 
faster and better clinical outcomes.
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